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Abstract
Transcription factor c-myc is frequently amplified/overexpressed in human cancers. One event 
c-myc controls is metabolic reprogramming or the addiction for glucose and/or glutamine as 
nutrients. Rewiring of metabolic circuitry provides cancer cells with a gain-of-survival advan-
tage. Accordingly, the aversion of two types of oncogenic-distinct metabolic addictions via 
c-myc control offers an anti-tumorigenic approach. Resveratrol reportedly inhibits the uptake/
transport of glucose or glutamine and reduces c-myc expression in cancer cells. Whether c-myc 
control by resveratrol involves quinone reductase NQO2 is unknown. NQO2 expressing 
(shRNA08) and knockdown (shRNA25) CWR22Rv1 prostate cancer cells were generated and 
used to study the role of NQO2 in growth and cell cycle control. Immunoblot analyses were 
used to evaluate the changes of cell cycle-associated proteins. NQO2 in mediating degradation 
of cyclin D1 via AKT/GSK-3β by resveratrol was tested by determining AKT and chymotryp-
sin-like proteasome activities. Molecular modeling and pull-down/deletion assays were used 
to evaluate the interaction between NQO2 and AKT. Resveratrol interacts with NQO2, a qui-
none reductase that plays a key role in resveratrol-induced AKT/GSK3β-mediated degradation 
of cyclin D1. In this chapter, we unravel control of expression and stability of c-myc by the res-
veratrol-NQO2 axis as an approach to overcome c-myc-mediated metabolic reprogramming.
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1. Introduction
The c-myc oncoprotein is a well-studied, multifunctional transcription factor that controls cell pro-
liferation, metabolism, and stress responses [1, 2]. Deregulation (amplification/overexpression) 
of c-myc occurs in many human cancers and is considered a “transition gatekeeper” for tumori-
genesis. c-Myc controls metabolic reprogramming, a key event in tumorigenesis that provides 
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gain-of-survival adaptive advantage, enabling cancers to thrive in tumor microenvironments 
with limited nutrient resources [3–5]. This rewiring of metabolic circuitry is characterized by (i) 
preferred use of glucose to produce ATP by aerobic glycolysis combined with increased lactate 
production even in oxygen abundance and (ii) dependence on glutamine for conversion to glu-
tamate and subsequent entry into the tricarboxylic acid cycle by anaplerosis [6, 7]. The metabolic 
calibration by c-myc in cancer cells is orchestrated to adequately meet the demands of energy 
expenditure, macromolecular syntheses, and disposal of catabolic wastes, in concordance with 
robust cell growth. For example, the capacity for aerobic glycolysis in highly proliferative cancer 
cells is controlled by c-myc via an increase in glucose uptake as a result of induced expression 
of glucose transporter 1 (Glut1) and lactate dehydrogenase (LDH) to stimulate glycolytic flux 
[8–12]. Similarly, to accommodate the utilization of glutamine, c-myc upregulates the level of 
expression of sodium-dependent neutral amino acid transporter (SLC1A5), thereby facilitating 
the transport of glutamate and uptake of glutamine. c-Myc also induces glutaminase GLS which 
catalyzes the conversion of glutamine to glutamate [8–10]. We hypothesize that the inhibition of 
c-myc expression and function, in addition to restriction of access to glucose/glutamine are both 
bona fide anti-carcinogenic approaches.
2. Metabolic addiction in malignant tumors presents new targets for 
cancer therapy
Cancer biology studies, for the past several decades, have focused on the identification and 
defining of DNA mutations, the narrowly centered focus being underpinned by the view-
point that cancer is largely a genetic disease. However, cancer cells are also endowed by the 
acquisition of several hallmarks that enable them to become tumorigenic; among them is the 
apparent rewiring of gene:metabolite circuitry coordinating an altered metabolic adaptation 
with dysregulated cell proliferation in cancer cells [13]. Thus, the ability of cancer cells to 
preferentially utilize glucose and aerobic glycolysis as a paradoxical coincidence with ample 
oxygen supply was historically made by Warburg in the 1920s [14]. The so-called Warburg 
phenomenon amply illustrates the oncogenic addiction for glucose as a rapidly established 
metabolic adaptation that increases the capacity for ATP generation to meet the energy 
demands for unrestricted tumor cell proliferation and metastasis [7, 13, 15–17]. A similarly 
disproportionate reliance on amino acid glutamine is found in various cancer types [3, 4], 
compared to normal cells [18, 19]. The elevated levels of glutamine metabolism in cancer 
provide nitrogen for nucleotide and amino acid biosynthesis, and additionally, direct citrate 
and isocitrate in the TCA cycle for use in lipid synthesis, namely, reprogramming glutamine 
for energy production and for biosynthetic reactions via anaplerosis [6, 7, 20]. This metabolic 
rewiring is now recognized as an “Achilles heel” for cancer therapy.
3. c-Myc regulates metabolic addiction, cell growth and 
tumorigenesis
c-Myc is a transcription factor that controls the expression of a large number of genes including 
those involved in ribosome and mitochondria biogenesis, glucose and glutamine metabolism, 
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and lipid biosynthesis [8, 11, 12, 21]. c-Myc controlled gene sets underpin bioenergetics and 
synthesis of building blocks required for macromolecular assembly, transformation, prolif-
eration and tumorigenesis. As a proto-oncogene, c-myc is frequently amplified/overexpressed 
in human cancers. Among a myriad of tumorigenic changes, c-myc controls are metabolic 
reprogramming—preferred use of glucose and glutamine, and sequential regulation of down-
stream targets/effectors [8, 11, 12, 21, 22]. c-Myc has been shown to induce the expression of 
glucose transporter Glut1 and glycolytic enzyme LDH to increase glycolytic flux. Similarly, 
c-myc also activates glutamine transporters SLC1A5 (also known as solute carrier family 1, 
member 5 and SLC38A5 - solute carrier family 38, member 5) that acts to increase uptake/
transport of glutamine [12]. The rewiring of metabolic programming by c-myc provides cancer 
cells with survival advantage by meeting the demands of energy expenditure, macromolecular 
syntheses, and catabolic waste disposal. Studies have also shown that upregulation of c-myc 
is associated with an increase in mitochondrial glutaminolysis, which plays an overarching 
role on glutamine addiction in cancer cells. c-Myc also induces GLS expression through a dual 
negative mechanism – suppression of miR-23a/b by c-myc, and inhibition of GLS expression 
by miR-23a/b [21, 23]. The upregulation of GLS by c-myc facilitates the coordination of meta-
bolic addiction with oncogenesis and the coalescence of metabolic calibration for survival with 
cellular transformation, proliferation, and cancer-related gene mutations. While metabolic 
addiction is clinically viewed as favoring carcinogenesis, it is equally plausible that the same 
nutrient dependence may become a restriction point for designing cancer therapy. Specifically, 
by limiting access to nutrients within the tumor microenvironments, novel oncogenic targets 
could become evident and are amenable for rational design of countermeasure strategies. A 
notable example can be found in the control of c-myc as a “master driver” for cancer; an equally 
appealing consideration likely involves the downstream targets regulated by c-myc [24, 25].
Resveratrol is a grape polyphenol whose efficacy has been amply supported by tissue culture and 
animal studies, and in limited clinical trials [26–30]. Resveratrol has been reported to inhibit c-myc 
in multiple cancer types including medulloblastoma cells, breast cancer cells and osteosarcoma 
[31–33]. How resveratrol inhibits c-myc via rewiring of metabolite:gene circuitry in tumorigenesis 
remains largely unknown and will be discussed in the next section. Greater understanding of this 
will add yet another dimension to the cancer preventive and therapeutic efficacy of resveratrol.
4. Aversion of c-myc metabolic addiction using resveratrol and its 
target protein NQO2 is an untested anti-tumorigenic approach
Since c-myc is involved in control of metabolic processing and resveratrol can inhibit c-myc 
expression, we propose that the c-myc-mediated metabolic dysregulation of cancer can be coun-
tered using grape-derived resveratrol. It is our hypothesis that resveratrol exerts a dual role in 
disrupting c-myc-mediated cancer metabolic reprogramming—a direct effect impinging on 
c-myc expression and stability and associated uptake/transport of glucose and/or glutamine, 
and an indirect effect involving NQO2 as the mediator affecting c-myc stability via AKT, its 
downstream effector GSK3β, and by extension control of the activity and function of the protea-
some. This provocative assignment for NQO2 greatly expands its cellular role from a cytosolic 
flavoprotein discovered in 1961 and classically considered phase II enzyme to a multi-tasking 
regulator involved in cancer cell metabolic reprogramming. Ample data support this postulation. 
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NQO2 requires NRH (N-ribosyl dihydronicotinamide) as the cosubstrate for catalysis; the bio-
synthetic source of NRH in mammalian cells has not been elucidated suggesting that NQO2 may 
have other novel cellular functions. Mouse keratinocyte studies show that NQO2 controls TNF-
induced NF-kB activation; NQO2 deletion potentiates the induction of apoptosis by abolishing 
TNF-induced cell survival kinases including JNK, AKT, p38, and p44/p42 MAPK [34]. NQO2 
stabilizes C/EBPα degradation mediated by 20S proteasomes [35]. We previously showed that 
NQO2 is a high affinity target protein of resveratrol: NQO2 binds resveratrol with K
D
 ≤ 50 nM 
[36]; X-ray crystal analysis shows that binding to resveratrol occurs in a hydrophobic pocket 
located between dimeric NQO2, possibly where the cosubstrate NRH binds [37]. Since the plasma 
concentration of resveratrol in humans can reach from 0.5 μM [38] to as high as 4 μM [39, 40], it 
may be suggested that in vivo levels of resveratrol are sufficient for binding and inhibiting NQO2 
enzyme activity and modulation of its other functions. One such novel role may pertain to control 
of c-myc turnover via T58 phosphorylation by AKT/GSK3β [41–43], results which agree with/
support/resemble our findings using NQO2-knockdown CWR22Rv1 cells, showing that NQO2: 
(i) inhibits AKT activity and (ii) controls cyclin D1 stability via AKT/GSK3β mediated threonine 
T-286 phosphorylation [44]. Moreover, oxidized and reduced NQO2 was recently reported to 
selectively bind DNA-intercalating agents, including ethidium bromide, acridine orange, and 
doxorubicin; all three agents functioning as inhibitors at nanomolar levels, thereby raising the 
provocative tenet that NQO2 is a potential regulator of eukaryotic gene transcription and expres-
sion [45]. Accordingly, activators/inhibitors of NQO2 may be developed as drug targets for the 
management of cancers harboring amplified/overexpressed transcriptional factor c-myc. As 
hypothesized, inhibitors of NQO2 could modify the interplay between NQO2 and c-myc and 
disrupt the c-myc-mediated growth advantage in cancer cells. If c-myc control is shown to be con-
nected to and under the rubric of genetic (NQO2) and/or chemical (resveratrol) mediated control 
in glucose/glutamine addiction cancer, then the control of NQO2-c-myc axis by resveratrol may 
be a promising cancer preventative and therapeutic lead, providing insights on how to better 
manage and treat glucose/glutamine addicted diseases.
5. Control of c-myc stability by NQO2
As a powerful factor governing the transcription of large gene sets that encode proteins 
playing critical roles in numerous cellular processes, both in normal and diseased states, 
the level of expression of c-myc is under stringent control. Ample data point to c-myc deg-
radation being regulated by sequential phosphorylation of S62 and T58, by two external 
signal activated kinase cascades, respectively, the RAF/MEK/ERK and PI3K/AKT/GSK3β 
signaling pathways [46–51]. T58 phosphorylation of c-myc promotes its interaction with the 
ubiquitin ligases Fbw7 and Skp2, ubiquitination and degradation by the proteasome [52–54]. 
Additionally, deubiquitinating enzymes, USP28 and USP36, also contribute to c-myc degra-
dation [54–56]. Of note, the reported AKT/GSK3β-mediated c-myc T58 phosphorylation in 
control of its turnover [41–43] is relevant to our own studies: (i) NQO2 is involved in AKT/
GSK3β-mediated cyclin D1 T286 phosphorylation and degradation and (ii) NQO2 knock-
down CWR22Rv1-sh25 cells show a 37% decrease in chymotrypsin-like proteasome activity 
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compared to control CWR22Rv1-sh08 cells [44]. These results suggest a hitherto-never-
considered aspect of control of c-myc stability by NQO2. Next, we will discuss a proposed 
study to test the potential role NQO2 plays as the mediator of control of c-myc stability via 
AKT/GSK3β-c-myc T-58 phosphorylation, and by regulation of activity and functioning of 
the proteasome.
Our previous studies showing that resveratrol exerts its effects via its target protein NQO2 
provide the impetus for testing that down regulation of c-myc by resveratrol requires the 
participation of NQO2. Based on our data that NQO2 affects cyclin D1 turnover, we expect 
that NQO2 will increase c-myc degradation, that is, ↓t1/2 instead of conferring protection on c-myc stability by competing against proteasome as has been reported for C/EBPα whose 
degradation by 20S proteasome is attenuated by NQO2 [35]. Since c-myc degradation by 
proteasomes is known to involve a multitude of mechanisms, there is a possibility resveratrol 
or NQO2 may directly affect c-myc degradation by exerting control on ubiquitin ligases like 
Fbw7 and Skp2 or the deubiquitinating enzyme, USP28. As to whether NQO2 interacts with 
AKT to affect AKT-GSK3β-mediated c-myc degradation, our expectation is that the accu-
mulated c-myc protein in MG132-treated cells will show a higher T58 phosphorylation as 
compared to nontreated control cells. As a corollary, addition of GSK3β inhibitor LiCl to 
treated cells should significantly reduce T58 phosphorylated c-myc protein, in parallel with 
an increase in c-myc protein accumulation. siRNA-knockdown of GSK-3α or -3β in NQO2 
expression cells compared to NQO2 knockdown cells will further confirm the role of GSK3β 
in mediating c-myc degradation. Results of these studies will provide support for the as yet 
untested hypothesis regarding the indirect role of NQO2 in controlling AKT → GSK3β → 
c-myc T58 phosphorylation → c-myc degradation by proteasome, and the direct role of res-
veratrol acting as a metabolic switch to shut off c-myc-mediated metabolic reprogramming 
in cancer cells.
6. Control of c-myc stability by resveratrol may involve the 
stimulation of proteasome β5 subunit
Epidemiological studies have shown that moderate intake of red wine is correlated with a 
reduced incidence of dementia and neurodegenerative disease [57]. Moreover, resveratrol, 
a tri-hydroxyl stilbene found in abundance in red wine, red grapes, peanuts and a num-
ber of other consumed foods in the United States, has been reported to confer protection 
against oxidative stress in PC-12 cells [58, 59]. It has been determined that the preeminent 
presence of senile plaques, composed mainly of amyloid-β (Aβ) deposits, is a pathological 
brain feature in individuals diagnosed with Alzheimer’s Disease (AD). The Aβ peptides 
are derived from cleavage of the amyloid-β precursor protein (APP) and have been shown 
to destabilize neurons and lead to cell death through the induction of oxidative stress, 
mediated by the generation of reactive oxygen species (ROS) and elevation in intracel-
lular hydrogen peroxide [60–62]. Compelling evidence supports that Aβ peptides serve as 
the “primary instigator” of AD [63]. Davies and coworkers[64] used tissue culture studies 
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combined with biochemical assays and siRNA-silencing approaches to show that resve-
ratrol lowered the levels of secreted and intracellular Aβ-peptides in a concentration and 
time-dependent manner. Further, this effect occurred not by targeting the Aβ-producing 
enzymes β and γ-secretases or by affecting the stability of APP or the turnover of its 
C-terminal fragments; but instead appeared to involve the promotion of intracellular deg-
radation of Aβ via a proteasome subunit β5-dependent mechanism. It is worth noting that 
resveratrol reportedly also promotes the proteasome-mediated degradation of important 
regulatory proteins, including cyclin D1 [65], the estrogen receptor-α [66], and the hypoxia-
inducible factor-1α [67].
7. c-Myc as an IDP (intrinsically disordered protein) may facilitate 
its turnover by resveratrol via a ubiquitin-independent, 20S 
proteasome-mediated mechanism
The notion that a folded three-dimensional structure is required for the biological function 
of a protein is dispelled by the discovery of intrinsically disordered proteins (IDPs) in the 
1990s [68]. IDPs can be viewed as proteins that have minimal structures or are devoid of 
an overall defined fold, either entirely or in parts and are more likely to exist in dynamic, 
mosaic states under physiological conditions. The absence of structural orderliness also con-
fers plasticity and “fussiness” to IDPs for diverse protein-protein interactions; however, the 
very same structural flexibility may also render them difficult and challenging as druggable 
targets using traditional structure-function drug design approaches.
Eukaryotic transcription factors perform important biological functions in control of gene 
expression. They play an essential role in identifying the target sequences on DNA located in 
the vicinity as well as far removed from the transcription start site through direct protein:nucleic 
acid interaction, and also are required for binding to a large array of co-transcription regula-
tory proteins via protein:protein interaction. As such, eukaryotic transcription factors have 
been shown to exhibit a high degree of intrinsic disorderliness; based on bioinformatic model 
prediction analysis it is estimated that more than 49% of human transcription factors contain 
intrinsic disorderliness [69]. Studies have also revealed that IDPs, because of their intrinsic 
destabilized nature circumventing the requirement for unfolding protein substrates for pro-
teolysis by the 26S proteasome, are more likely to be degraded via an ubiquitin-independent 
mechanism using the 20S proteasomes [70].
The intrinsically unstructured protein (IUP), disorderly theme is also found in transcription 
factor c-myc; indeed, c-myc only attains an ordered structure after binding to its disordered 
partner MAX protein (myc-associated factor). Bioinformatics and experimental approaches 
have estimated that c-myc contains more than 45% of residues which have high prob-
ability for disordered structure formation [71]. The possession of intrinsically disordered 
regions allows c-myc to be degraded independently of ubiquitin, which may account for its 
observed short half-life at the mRNA [72–74] and protein levels [75–77], and is dynamically 
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aligned with its switch on/off master transcriptional role independent of collaborative 
interaction with the pool of cellular ubiquitin that drives 26S proteasome-mediated protein 
degradation.
It should be noted that the function of the 20S proteasome can also be modulated by interaction 
with NAD(P)H:quinone oxidoreductase 1 and 2 (NQO1 and NQO2). Previous studies have 
reported that NQO1 physically binds the 20S proteasome in an NADH-dependent manner 
[78–80] and to protect IDPs from degradation [81]. A double negative feedback mechanism 
exists between NQO1 and the 20S proteasome [78]. On the one hand, NQO1 acts to attenuate 
the proteolytic activity of the proteasome; on the other hand, the proteasome degrades the 
NQO1 FAD-free apo form which manifests as a partially unfolded structure and a substrate 
for the 20S proteasome [81]. Studies have shown that NQO2 confers protection against pro-
teolytic degradation by the 20S proteasome [35, 82] albeit by a mechanism independent of 
NQO1 [83].
8. Conclusion
Resveratrol has been shown to inhibit the uptake/transport of glucose or glutamine, and 
decrease the expression of c-myc in cancer cells. Rewiring of metabolite:gene circuitry is a key 
event in tumorigenesis that has been known for decades [7, 15–17], however, with an incom-
pletely understood underlying mechanism. In this chapter, we discuss the aversion of c-myc-
mediated reprogrammed cancer cell metabolism by targeting the expression and stability 
of c-myc using a chemical/genetic disruptive approach focusing on resveratrol and its high 
affinity target NQO2 we identified [36]. Additionally, the hypothesis we propose broadens 
the classical function of NQO2 in quinone detoxification to AKT/c-myc-mediated metabolic 
reprogramming observable in a clinical setting. Taken together, resveratrol/NQO2 in a c-myc 
controlling role to block metabolic addiction represents a novel diet-based chemoprevention 
approach in concept, and is transformative in implications warranting further investigation. 
The results will lay foundation for discovery of drugs able to disrupt AKT/c-myc-mediated 
reorganized metabolism using NQO2 inhibitors.
In summary, we advance the thesis to avert c-myc-mediated metabolic reprogramming in 
cancer cells by targeting the control of c-myc and the uptake and metabolism of glucose 
and glutamine and their downstream effectors using resveratrol. We propose to focus on 
control of phosphorylation of c-myc T58 by GSK3β, shown to be critical for proteasome 
mediated c-myc degradation, by the resveratrol target protein NQO2 which we have previ-
ously shown to act as a modulator of AKT/GSK3β proteasome mediated degradation of 
cyclin D1 [44].
The dual role resveratrol plays in disrupting c-myc-mediated metabolic reprogramming in 
cancer cells—a direct role targeting suppression of c-myc expression and an indirect role 
involving NQO2-AKT-GSK 3β mediated increase in c-myc T58-phosphorylation for increased 
degradation by proteasome—is illustrated in Figure 1.
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